Market closed

Ligand Pharmaceuticals/$LGND

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ticker

$LGND

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Jupiter, United States

Employees

Website

www.ligand.com

LGND Metrics

BasicAdvanced

$2B

42.83 $2.47

0.90 -

Price and volume

Market cap

$2B

Beta

0.9

52-week high

$123.20

52-week low

$67.53

Average daily volume

118K

Financial strength

Current ratio

12.489

Quick ratio

10.567

Long term debt to equity

0.745

Total debt to equity

0.875

Interest coverage (TTM)

27.40%

Management effectiveness

Return on assets (TTM)

1.30%

Return on equity (TTM)

6.00%

Valuation

Price to earnings (TTM)

42.829

Price to revenue (TTM)

12.441

Price to book

2.32

Price to tangible book (TTM)

4.23

Price to free cash flow (TTM)

75.234

Growth

Revenue change (TTM)

-0.76%

Earnings per share change (TTM)

160.46%

3-year revenue growth (CAGR)

-17.82%

3-year earnings per share growth (CAGR)

-15.15%

What the Analysts think about LGND

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.

LGND Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

LGND Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

LGND News

AllArticlesVideos

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Seeking Alpha·1 day ago

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Seeking Alpha·2 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LGND

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals (LGND) has a market cap of $2B as of January 15, 2025.

What is the P/E ratio for Ligand Pharmaceuticals stock?

The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 42.83 as of January 15, 2025.

Does Ligand Pharmaceuticals stock pay dividends?

No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Ligand Pharmaceuticals dividend payment date?

Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.

What is the beta indicator for Ligand Pharmaceuticals?

Ligand Pharmaceuticals (LGND) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.